G1 Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Okay. I'll get started. Appreciate the opportunity to share the G1 story in this virtual conference, and want to thank the organizers at Barclays and Peter Lawson, who, I know, will be joining for the Q&A. We do have an abbreviated deck posted on our website as well as our latest corporate overview. I'll just make a few high-level comments and then go to Q&A.
We're a clinical stage oncology company. We were founded by Dr. Ned Sharpless when he was Head of the Cancer Center at UNC. He's currently Director of the National Cancer Institute. We went public in 2017, and we've advanced 3 therapeutic candidates from preclinical to meaningful clinical data and are looking at the first approval of our lead program, trilaciclib, as we file an NDA in 2020. A very experienced team, an independent Board of Directors, and we're headquartered here in Research Triangle Park, North Carolina.
We're advancing 3 innovative therapeutic candidates, the lead, trilaciclib, which is our first-in-class myelopreservation therapy
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
